Table 3.

Outcome measures in the EXERPHARMA trial

	Collection time points
Primary end point
Knee biomechanics (mean ±95% CI):	0, 8 weeks
Knee index, during gait
Secondary end points:
Knee biomechanics (mean ±95% CI):	0, 8 weeks
Knee Index, during one-leg rise
Peak Knee Adduction Moment, during gait
Peak Knee Adduction Moment, during one-leg rise
Knee Adduction Moment Impulse, during gait
Knee Adduction Moment Impulse, during one-leg rise
Functional performance test (mean ±95% CI):	0, 8 weeks
Maximum one-leg rises from stool
Maximum number of knee-bendings in 30-second test
One-leg hop for distance test
Patient-reported outcomes:
Mean KOOS subscale scores (mean ±95% CI):	0, 8, 52 weeks
Pain
Other symptoms
Activities of Daily Living (ADLs)
Sport and Recreation Function
Knee-related Quality of Life (QOL)
Activity level:
UCLA activity score, change from baseline	0, 8, 52 weeks
Pain level:
Pain-level text messages, intensity (0–4)	During treatment